Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Aβ peptide

Nanomedicine. 2017 Feb;13(2):723-732. doi: 10.1016/j.nano.2016.10.006. Epub 2016 Oct 19.

Abstract

Aggregation of amyloid-β peptide (Aβ) is a key event in the pathogenesis of Alzheimer's disease (AD). We investigated the effects of nanoliposomes decorated with the retro-inverso peptide RI-OR2-TAT (Ac-rGffvlkGrrrrqrrkkrGy-NH2) on the aggregation and toxicity of Aβ. Remarkably low concentrations of these peptide inhibitor nanoparticles (PINPs) were required to inhibit the formation of Aβ oligomers and fibrils in vitro, with 50% inhibition occurring at a molar ratio of ~1:2000 of liposome-bound RI-OR2-TAT to Aβ. PINPs also bound to Aβ with high affinity (Kd=13.2-50 nM), rescued SHSY-5Y cells from the toxic effect of pre-aggregated Aβ, crossed an in vitro blood-brain barrier model (hCMEC/D3 cell monolayer), entered the brains of C57 BL/6 mice, and protected against memory loss in APPSWE transgenic mice in a novel object recognition test. As the most potent aggregation inhibitor that we have tested so far, we propose to develop PINPs as a potential disease-modifying treatment for AD.

Keywords: Alzheimer's disease; Liposomes; Oligomer; Retro-inverso peptide; β-amyloid.

MeSH terms

  • Alzheimer Disease / physiopathology*
  • Alzheimer Disease / therapy*
  • Amyloid beta-Peptides
  • Animals
  • Blood-Brain Barrier
  • Humans
  • Liposomes
  • Mice, Transgenic
  • Nanoparticles*
  • Peptide Fragments*
  • Tumor Cells, Cultured

Substances

  • Amyloid beta-Peptides
  • Liposomes
  • Peptide Fragments